Keyphrases
Carboplatin
100%
Chemotherapy Regimen
100%
Elderly Patients
100%
Platinum-based Chemotherapy
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Comparative Effectiveness
100%
Carboplatin-paclitaxel
70%
Gemcitabine
60%
Docetaxel
50%
Confidence Interval
30%
Propensity Score
30%
Hazard Ratio
20%
Histology
20%
Multivariable
20%
Stratified Analysis
20%
First-line Chemotherapy
20%
High Risk
10%
Risk of Death
10%
Medicare Beneficiaries
10%
Randomized Trial
10%
Cox Proportional Hazards Model
10%
Overall Survival
10%
Non-small Cell Lung Cancer (NSCLC)
10%
Median Survival
10%
Patient Characteristics
10%
Platinum-based
10%
Cox Model
10%
Medicare
10%
Squamous Carcinoma
10%
Mortality Hazard
10%
Surveillance Epidemiology
10%
Relative Effectiveness
10%
Trial Reporting
10%
Squamous Cell
10%
Non-squamous
10%
Propensity Score Analysis
10%
Medicare Population
10%
Chemotherapy Agents
10%
Stratified Model
10%
Nonsquamous Histology
10%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Carboplatin
100%
Chemotherapy Regimens
100%
Paclitaxel
35%
Gemcitabine
35%
Docetaxel
29%
First-Line Chemotherapy
11%
Overall Survival
5%
Squamous Cell Carcinoma
5%
Chemotherapy Agent
5%